Allarity Therapeutics (NASDAQ:ALLR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Allarity Therapeutics (NASDAQ:ALLR) announced its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04, FiscalAI reports.

Allarity Therapeutics Trading Up 0.7%

Shares of ALLR stock traded up $0.01 during mid-day trading on Friday, reaching $1.37. The stock had a trading volume of 45,373 shares, compared to its average volume of 163,868. Allarity Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.35. The business has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $1.26. The company has a market cap of $21.80 million, a P/E ratio of -1.90 and a beta of 0.51.

Institutional Trading of Allarity Therapeutics

A number of large investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in shares of Allarity Therapeutics in the fourth quarter valued at approximately $36,000. DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics in the fourth quarter worth approximately $133,000. Renaissance Technologies LLC increased its position in Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Allarity Therapeutics in the 3rd quarter worth $149,000. Finally, Private Advisor Group LLC acquired a new position in shares of Allarity Therapeutics in the 3rd quarter valued at about $441,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ALLR shares. Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets boosted their price target on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. Finally, Wall Street Zen raised shares of Allarity Therapeutics to a “hold” rating in a research report on Saturday, May 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.25.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.